Journal article

Subcortical brain structure and suicidal behaviour in major depressive disorder: a meta-analysis from the ENIGMA-MDD working group

ME Renteria, L Schmaal, DP Hibar, B Couvy-Duchesne, LT Strike, NT Mills, GI de Zubicaray, KL McMahon, SE Medland, NA Gillespie, SN Hatton, J Lagopoulos, DJ Veltman, N van der Wee, TGM van Erp, K Wittfeld, HJ Grabe, A Block, K Hegenscheid, H Voelzke Show all

TRANSLATIONAL PSYCHIATRY | NATURE PUBLISHING GROUP | Published : 2017

Abstract

The aetiology of suicidal behaviour is complex, and knowledge about its neurobiological mechanisms is limited. Neuroimaging methods provide a noninvasive approach to explore the neural correlates of suicide vulnerability in vivo. The ENIGMA-MDD Working Group is an international collaboration evaluating neuroimaging and clinical data from thousands of individuals collected by research groups from around the world. Here we present analyses in a subset sample (n=3097) for whom suicidality data were available. Prevalence of suicidal symptoms among major depressive disorder (MDD) cases ranged between 29 and 69% across cohorts. We compared mean subcortical grey matter volumes, lateral ventricle vo..

View full abstract

Grants

Awarded by NIH BD2K award


Awarded by Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence on Suicide Prevention (CRESP)


Awarded by Australian National Health and Medical Research Council


Awarded by Netherlands Organisation for Health Research and Development (Zon-Mw)


Awarded by Netherlands Brain Foundation


Awarded by Neuroscience Campus Amsterdam Scientific Excellence


Awarded by German Research Foundation


Awarded by Deutsche Forschungsgemeinschaft/German Research Association


Awarded by German Federal Ministry of Education and Research


Awarded by EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT


Awarded by NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING


Awarded by NATIONAL INSTITUTE ON DRUG ABUSE


Awarded by Medical Research Council


Funding Acknowledgements

The ENIGMA-Major Depressive Disorder working group gratefully acknowledges support from the NIH BD2K award, U54EB020403. MER, NGM, HC and IBH received support from the Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence on Suicide Prevention (CRESP) [GNT1042580]. QTIM: Australian National Health and Medical Research Council (Project Grants No. 496682 and 1009064 to MJW and Fellowship No. 464914 to IBH), US National Institute of Child Health and Human Development (RO1HD050735 to MJW) and US National Institute on Drug Abuse (R00DA023549 to NAG). BC-D is supported by a University of Queensland International PhD scholarship. NESDA: The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht programme of the Netherlands Organisation for Health Research and Development (Zon-Mw, grant number 10-000-1002) and is supported by participating universities (VU University Medical Center, GGZ inGeest, Arkin, Leiden University Medical Center, GGZ Rivierduinen, University Medical Center Groningen) and mental health care organizations, see www.nesda.nl. LS is supported by The Netherlands Brain Foundation Grant number F2014(1)-24 and the Neuroscience Campus Amsterdam Scientific Excellence grant (IPB-SE-15-PSYCH-Schmaal). CODE: The CODE cohort was collected from studies funded by Lundbeck and the German Research Foundation (WA 1539/4-1, SCHN 1205/3-1). ES is supported by the Grant of the Deutsche Forschungsgemeinschaft/German Research Association (SCHR443/11-1). SHIP: The Study of Health in Pomerania (SHIP) is supported by the German Federal Ministry of Education and Research (grants 01ZZ9603, 01ZZ0103 and 01ZZ0403) the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania. magnetic resonance imaging scans were supported by Siemens Healthcare, Erlangen, Germany. SHIP-LEGEND was supported by the German Research Foundation (GR1912/5-1). CK received fees for an educational programme from Esparma/Aristo Pharma, Lilly, Servier and MagVenture, as well as travel support and speakers honoraria from Lundbeck and Servier. TGMvE consulted for Roche Pharmaceuticals in 2013-2014.